Every Form 4 that Zai Lab Limited (ZLAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZLAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZLAB filings page.
Zai Lab Ltd (ZLAB) reported that its Chief Financial Officer, Chen Yajing, sold 260 American Depositary Shares (ADS) of the company on 2026-08-19 at $27.00 per ADS. Following this sale, Chen directly holds 35,635 ADS. Each ADS represents ten Ordinary Shares, and the ADSs and Ordinary Shares are described as fully fungible. The sale was effected under a Rule 10b5-1 trading plan adopted on December 9, 2025.
Zai Lab Ltd (ZLAB) reported an insider equity compensation event for its Chief Financial Officer, Yajing Chen. On 2026-08-14, 1,250 Restricted Share Units (RSUs) vested and were settled into 1,250 American Depositary Shares (ADSs), with each RSU delivering one ADS. Each ADS represents ten Ordinary Shares, and the company reports these holdings in ADS terms. On the same date, 427 ADSs were withheld at $25.90 per ADS to cover tax obligations arising from the vesting, leaving the remainder of the vested ADSs delivered to the reporting person. Following this vesting event, 1,250 RSUs remain outstanding and will continue to vest in equal annual installments over four years beginning on 2024-08-14, with vested shares delivered in ADS form.
Zai Lab Ltd director William Lis reported selling 8,506 American Depositary Shares (ADS) of the company on August 12, 2026 at $25.00 per ADS, in an open-market or private sale. The transaction was effected under a Rule 10b5-1 trading plan adopted on September 10, 2025. Following this sale, Lis directly holds 41,931 ADS, with each ADS representing ten ordinary shares.
Zai Lab Ltd Chief Financial Officer Chen Yajing sold 619 American Depositary Shares (ADS) on August 11, 2026 at $25.00 per ADS, leaving 35,072 ADS held directly. Each ADS represents ten Ordinary Shares. The sale was executed under a Rule 10b5-1 trading plan adopted on December 9, 2025.
Zai Lab Ltd director Richard Gaynor executed an open-market purchase of 1,736 American Depositary Shares (ADS) on July 1, 2026 at $19.05 per ADS. Each ADS represents ten ordinary shares, and ADSs and ordinary shares are fully fungible.
Following this transaction, Gaynor directly holds 80,737 ADS. The trade was carried out under a Rule 10b5-1 trading plan that he adopted on December 16, 2025, meaning the purchase was pre-scheduled rather than timed discretionarily.
Zai Lab Ltd director and CEO Du Ying reported compensation-related equity activity involving American Depositary Shares (ADSs) and Restricted Share Units (RSUs). On July 1–2, 2026, Ying exercised RSUs to acquire a total of 29,048 ADSs, with no open-market purchases or sales.
To cover tax obligations upon RSU vesting, 11,431 ADSs were withheld, a non-market disposition method. Ying also received a new grant of 80,393 RSUs, each representing a contingent right to one ADS, vesting annually over four years subject to continuous service.
Following these transactions, Ying directly held 1,221,401 ADSs. RSUs continue to vest in equal annual installments, and vested shares will be delivered in ADS form to Ying after each vesting date.
Zai Lab Ltd Chairperson & CEO Du Ying reported routine equity compensation activity involving American Depositary Shares (ADSs). On June 29, 2026, Restricted Share Units (RSUs) representing 17,970 ADSs were exercised, with each RSU converting into one ADS and each ADS representing ten ordinary shares.
On June 30, 2026, 7,026 ADSs were sold in the open market at $18.534 per ADS. Footnotes state these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, Du Ying directly held 1,203,784 ADSs.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III exercised equity awards and sold shares mainly to cover taxes. On June 25, 2026, he converted 14,600 Restricted Share Units into the same number of American Depositary Shares (ADSs), at a $0.00 exercise price, as part of his compensation vesting schedule.
On June 26, 2026, 4,103 ADSs were sold at an average price of $17.461 per ADS, with a footnote stating the ADSs were sold automatically to cover taxes upon vesting of RSUs. After these transactions, he directly owned 30,346 ADSs, and the RSU award referenced in the filing was fully settled.
Zai Lab Ltd Chairperson and CEO Ying Du reported compensation-related share activity involving American Depositary Shares (ADSs). On June 25, 2026, 58,800 ADSs were acquired upon vesting of Restricted Share Units (RSUs), with each RSU converting into one ADS and each ADS representing ten ordinary shares. On June 26, 2026, 24,543 ADSs were sold at $17.461 per ADS to cover taxes due on the RSU vesting, leaving a net of 34,257 ADSs from this award. Following these transactions, Ying Du directly owns 1,192,840 ADSs.
Zai Lab Ltd Chief Financial Officer Yajing Chen reported routine equity compensation activity involving American Depositary Shares (ADSs). On June 25, 6,250 Restricted Share Units (RSUs) vested, resulting in the acquisition of 6,250 ADSs, with each RSU converting into one ADS at no cash cost. Each ADS represents ten ordinary shares. On June 26, 2,264 of these ADSs were sold automatically to cover tax obligations associated with the vesting, rather than as a discretionary portfolio sale. Following these transactions, Chen directly holds 35,691 ADSs, reflecting a net increase in ownership and no remaining RSUs from this specific grant.
Zai Lab Ltd director William Lis sold 7,040 American Depositary Shares in an open-market transaction. The sale occurred at a price of $18.09 per ADS. After this transaction, he directly holds 50,437 ADS.
Each ADS represents ten Ordinary Shares, and the company states that ADSs and Ordinary Shares are fully fungible. The sale was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2025, indicating the trades were pre-arranged rather than opportunistic.
GAYNOR RICHARD reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Richard Gaynor received a stock grant in the form of American Depositary Shares (ADSs). On June 17, 2026, he was awarded 22,371 ADSs at no cash cost as a compensation-related grant. Following this award, he directly holds 79,001 ADSs. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are fully fungible. The granted shares are restricted and will vest in full on June 17, 2027, provided he continues to serve on the company’s board of directors through that date.
Morrison Scott W reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Morrison Scott W received a grant of 22,371 American Depositary Shares as equity compensation. The award was made at a price of $0.00 per ADS and consists of restricted shares that vest in full on June 17, 2027, contingent on his continued board service. Following this grant, he directly holds a total of 56,904 ADS. Each ADS represents ten ordinary shares of Zai Lab, and the filing reports all amounts in ADS terms.
Vounatsos Michel reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Michel Vounatsos received an equity award of 22,371 American Depositary Shares (ADS), reported at a price of $0.00 per ADS, as a grant or award. These are restricted shares that vest in full on June 17, 2027, if he continues serving on the board through that date.
Following this grant, Vounatsos directly holds 72,787 ADS. Each ADS represents ten ordinary shares of Zai Lab, and the company states that its ADSs and ordinary shares are fully fungible.
Lis William reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director William Lis received a grant of 22,371 American Depositary Shares as equity compensation. The award was made at no cash cost per ADS and increases his direct holdings to 57,477 ADS.
The granted ADS are restricted shares that vest in full on June 17, 2027, if he continues serving on the board. Each ADS represents ten ordinary shares, and the company notes that ADSs and ordinary shares are fully fungible.
WIRTH PETER reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Peter Wirth received a grant of 22,371 American Depositary Shares (ADSs) as a stock award. The filing notes these are restricted shares that vest in full on June 17, 2027, if he continues serving on the board. After this grant, he directly holds 416,121 ADSs. Each ADS represents ten ordinary shares, and the award was made at no cash purchase price, reflecting equity-based director compensation rather than an open-market share purchase.
DIEKMAN JOHN D reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director John D. Diekman received an equity award of 22,371 American Depositary Shares as a grant, with no cash paid per share. These are restricted shares that will vest in full on June 17, 2027, as long as he continues serving on the board through that date. Following this award, he directly holds a total of 122,140 American Depositary Shares in the company.
MOULDER LEON O JR reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Leon O. Moulder Jr received a grant of 22,371 American Depositary Shares (ADS) as a compensation award. The shares were granted at $0.00 per ADS and are described as restricted shares that vest in full on June 17, 2027, if he continues serving on the board. Each ADS represents ten ordinary shares of Zai Lab, and following this grant he directly holds 94,973 ADS in total. This is a stock-based award rather than an open-market purchase or sale.
Leung Nisa reported acquisition or exercise transactions in this Form 4 filing.
Zai Lab Ltd director Nisa Leung received a stock grant of 22,371 American Depositary Shares (ADS) as compensation. These are restricted shares that vest in full on June 17, 2027, contingent on her continued service on the board. Following this award, she directly holds 96,297 ADS in total.
Zai Lab Ltd reported that officer Wang Yizhe, an Operating Partner, received new equity awards in the form of restricted share units and stock options. The grant includes 59,288 Restricted Share Units, each representing a contingent right to receive one American Depositary Share (ADS).
Wang also received 136,819 stock options to buy ADSs at an exercise price of $20.32 per ADS, expiring on May 11, 2036. Both the RSUs and options vest in equal annual installments over four years beginning on May 11, 2027, subject to continuous service. Each ADS represents ten ordinary shares, and the company notes that ADSs and ordinary shares are fully fungible.
Zai Lab Ltd Chairperson and CEO Du Ying reported a series of bona fide gifts of American Depositary Shares (ADSs). On May 26 and 27, 2026, Du Ying gifted a total of 107,700 ADSs in three transactions to trusts established for the benefit of an adult son. Each ADS represents ten Ordinary Shares of the company. After these transfers, Du Ying continues to hold 1,158,583 ADSs directly, indicating a substantial remaining ownership position.
Zai Lab Ltd Chairperson & CEO Du Ying reported routine equity compensation activity involving American Depositary Shares (ADSs). On May 19, Du Ying exercised stock options to acquire 261,092 ADSs at an exercise price of $1.74 per ADS and simultaneously used 117,435 ADSs, valued at $18.75 per ADS, to satisfy tax obligations through a tax-withholding disposition. Following these transactions, Du Ying directly held 1,266,283 ADSs. Each ADS represents ten ordinary shares of Zai Lab, and the activity was carried out under a pre-arranged Rule 10b5-1 trading plan. The filing shows an exercise-and-hold pattern with part of the shares applied to taxes and no open-market sale.
Zai Lab Ltd Chairperson and CEO Du Ying reported option exercises and share sales in American Depositary Shares (ADS). On May 15 and May 18, Du Ying exercised stock options to acquire a total of 100,000 ADS at an exercise price of $1.74 per ADS and sold 100,000 ADS in open-market transactions.
The reported weighted average sale prices were $20.7422 and $18.9953 per ADS, with individual trades executed within disclosed price ranges. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025. Following the transactions, Du Ying directly holds 1,122,626 ADS.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an open-market sale of 3,517 American Depositary Shares (ADS) on May 14, 2026 at a price of $20.19 per ADS. Each ADS represents ten Ordinary Shares of Zai Lab.
Following the transaction, he directly holds 19,849 ADS. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Zai Lab Ltd Chairperson and CEO Du Ying reported option exercises and share sales in American Depositary Shares (ADSs). On May 13–14, 2026, Du Ying exercised stock options to acquire 100,000 ADSs at a price of $1.74 per ADS equivalent, then sold 100,000 ADSs in open-market transactions at weighted average prices of $19.4432, $20.2223, and $20.0915 per ADS.
After these transactions, Du Ying directly holds 1,122,626 ADSs and 361,092 stock options outstanding. All trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025, indicating the timing was set in advance rather than decided opportunistically.
Zai Lab Ltd officer Joshua L. Smiley reported an automatic tax-related sale of company stock. On April 6, 2026, he sold 3,017 American Depositary Shares (ADSs) at $20.448 per ADS to cover taxes due upon vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of Zai Lab. After this tax-cover transaction, Smiley directly held 117,602 ADSs, indicating he retained a substantial equity position in the company.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an automatic sale of 1,224 American Depositary Shares (ADSs) of Zai Lab Ltd to cover taxes upon vesting of Restricted Share Units. The ADSs were sold at an average price of $20.448 per ADS on April 6, 2026.
Each ADS represents ten Ordinary Shares of Zai Lab Ltd. Following this tax-related sale, Edmondson Frazor Titus III directly holds 23,366 ADSs. The transaction reflects a routine disposition tied to equity compensation rather than a discretionary open-market trade.
Zai Lab Ltd Chairperson and CEO Ying Du reported an open-market sale of 2,653 American Depositary Shares (ADSs) of the company at a price of $20.448 per ADS. A filing footnote explains these ADSs were sold automatically to cover taxes upon vesting of Restricted Share Units.
After this tax-related sale, Ying Du directly holds 1,122,626 ADSs. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are fully fungible.
Zai Lab Ltd Chief Financial Officer Yajing Chen reported an open-market sale of 853 American Depositary Shares (ADSs) of Zai Lab on April 6, 2026 at an average price of $20.448 per ADS. Each ADS represents ten ordinary shares, and the company states its ADSs and ordinary shares are fully fungible, though this report is presented in ADS terms.
According to the disclosure, these ADSs were sold automatically to cover taxes triggered by the vesting of Restricted Share Units, indicating a tax-withholding related transaction rather than a discretionary portfolio decision. After this sale, Chen directly holds 31,705 ADSs, showing that the transaction affects only a small portion of her reported direct holdings.
Zai Lab Ltd officer Rafael Amado reported an open-market sale of 2,739 American Depositary Shares (ADSs) at $20.448 per ADS. Each ADS represents ten ordinary shares. After the transaction, he directly holds 57,022 ADSs.
According to the filing, these ADSs were sold automatically to cover taxes due upon the vesting of Restricted Share Units, indicating the sale was driven by tax obligations rather than a discretionary portfolio decision.
Zai Lab Ltd Chairperson and CEO Du Ying reported routine equity compensation activity. On April 1–2, 2026, she exercised vested restricted share units, receiving 20,950 American Depositary Shares (ADSs), each representing ten ordinary shares. Of these, 5,576 ADSs were sold automatically at $20.39 per ADS to cover taxes due at vesting.
After these transactions, Du Ying directly holds 1,125,279 ADSs. Earlier, on March 4, 2026, performance conditions were confirmed for 25,579 performance-based share units, each representing a contingent right to one ADS. These PSUs vest in full on July 2, 2028, subject to continuous service.
Zai Lab Ltd Chief Financial Officer Chen Yajing reported several equity compensation transactions in American Depositary Shares (ADSs), each ADS representing ten ordinary shares. On April 1–2, 2026, Chen acquired a total of 17,758 ADSs through the vesting and settlement of Restricted Share Units (RSUs) at an exercise price of $0.00 per ADS.
On April 2, 2026, 5,199 ADSs were sold at $20.39 per ADS, and the footnotes state these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, Chen directly held 32,558 ADSs.
Separately, on March 4, 2026, Chen was granted 11,924 performance-based share units (PSUs), each representing a contingent right to receive one ADS. The performance-based vesting conditions for these PSUs, tied to criteria measured between January 1, 2025 and December 31, 2025, were confirmed, and the PSUs vest in full on March 12, 2028, subject to continuous service.
Zai Lab Ltd officer Rafael Amado reported equity compensation activity and related tax sales in American Depositary Shares (ADSs), each representing ten ordinary shares. On April 1–2, 2026, he acquired a total of 24,914 ADSs through vesting and conversion of Restricted Share Units (RSUs) at a conversion price of $0.00 per ADS.
On April 2, 2026, 9,910 ADSs were sold at $20.39 per ADS, and the footnotes state these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, he directly held 59,761 ADSs.
Separately, on March 4, 2026, Amado was credited with 14,905 performance-based share units (PSUs), representing a contingent right to receive the same number of ADSs. The performance-based vesting conditions for these PSUs, originally granted on March 12, 2025, were confirmed based on 2025 performance, and the PSUs will vest in full on March 12, 2028, subject to continuous service.
Zai Lab Ltd’s Chief Legal Officer, Edmondson Frazor Titus III, reported several equity compensation changes. He exercised restricted share units into a total of 22,290 American Depositary Shares (ADSs) at a conversion price of $0.00 per ADS-equivalent. Of these, 4,194 ADSs were automatically sold at $20.39 per ADS to cover taxes upon vesting, while the remainder were retained. He also received a grant of 11,924 performance-based share units tied to future ADS delivery. Following these transactions, he directly holds 24,590 ADSs.
Zai Lab Ltd officer Joshua L. Smiley reported multiple equity compensation transactions involving American Depositary Shares (ADSs) and share units. On April 1, 2026, RSUs vested into 32,062 ADSs, and on April 2, 2026, additional RSUs vested into 7,145 ADSs, each RSU converting into one ADS at a price of $0.00 per unit.
On April 2, 2026, 9,614 ADSs were sold at $20.39 per ADS, with a footnote stating these shares were sold automatically to cover taxes upon RSU vesting. After these transactions, Smiley directly owned 120,619 ADSs. Separately, on March 4, 2026, he was credited with 17,887 performance-based share units, each representing a contingent right to receive one ADS, following satisfaction of 2025 performance criteria; these PSUs vest in full on March 12, 2028 subject to continuous service. RSUs referenced in the filing vest in equal annual installments over four years, with vested shares delivered in ADS form.
Zai Lab Ltd director Richard Gaynor bought 1,731 American Depositary Shares in an open‑market transaction at $18.91 per ADS. After this purchase, he directly holds 56,630 ADS. The trade was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 16, 2025.
Zai Lab Ltd reported that officer Joshua L. Smiley received new equity awards and completed routine vesting and tax-related sales. On March 4, 2026, he was granted 103,950 stock options with an exercise price of $19.27 per ADS and 33,783 restricted share units (RSUs), each RSU representing one American Depositary Share (ADS). These options and RSUs vest in equal annual installments over four years beginning on March 4, 2027, subject to continuous service. On March 12, 2026, 6,388 RSUs vested and were settled in ADSs, and on March 13, 2026, 1,966 ADSs were sold at $18.628 per ADS automatically to cover taxes. After these transactions, Smiley directly holds 91,026 ADSs, along with remaining RSU and option awards scheduled to vest over time.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported multiple equity compensation moves. On March 4, 2026, he received stock options for 83,160 American Depositary Shares (ADSs) at an exercise price of $19.27 per ADS, expiring on March 4, 2036, plus 27,027 Restricted Share Units (RSUs). Both awards vest in equal annual installments over four years beginning in 2027, subject to continuous service.
On March 12, 2026, 4,258 RSUs were exercised into the same number of ADSs, and on March 13, 2026 he sold 1,281 ADSs at $18.628 per ADS. Footnotes state these ADSs were sold automatically to cover taxes upon vesting of RSUs. After these transactions, he directly holds 6,494 ADSs.
Zai Lab Ltd Chief Financial Officer Yajing Chen received new equity compensation and reported related share activity. On March 4, 2026, Chen was granted 83,160 stock options with an exercise price of $19.27 per American Depositary Share (ADS), expiring on March 4, 2036, and 27,027 Restricted Share Units (RSUs). These options and RSUs vest in equal annual installments over four years beginning on March 4, 2027, subject to continuous service.
On March 12, 2026, 4,258 RSUs vested and converted into the same number of ADSs, and on March 13, 2026, 1,703 ADSs were sold at $18.628 per ADS. According to the footnotes, these ADSs were sold automatically to cover taxes due upon RSU vesting, rather than as a discretionary open-market sale. After these transactions, Chen held 19,999 ADSs directly.
Zai Lab Ltd officer Rafael Amado reported compensation-related equity activity and a small share sale. He received stock options for 103,950 American Depositary Shares (ADSs) at an exercise price of $19.27 per ADS, expiring in 2036, and 33,783 Restricted Share Units (RSUs) linked to ADSs.
On March 12, 2026, 5,323 RSUs were exercised into the same number of ADSs, increasing his direct ADS holdings. On March 13, 2026, he sold 2,957 ADSs at $18.628 per ADS, with a footnote stating these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, he directly held 44,757 ADSs and 15,971 RSUs. Each ADS represents ten ordinary shares.
Zai Lab Ltd reported new equity awards to Chairperson and CEO Ying Du. On March 11, 2026, Du received stock options for 353,430 American Depositary Shares (ADSs) with an exercise price of 19.34 per ADS, expiring on March 11, 2036.
The filing also shows a grant of 32,419 Restricted Share Units (RSUs), each representing one ADS. Both the options and RSUs vest in equal annual installments over four years beginning on March 11, 2027, subject to continuous service. Each ADS represents ten ordinary shares of Zai Lab.
Zai Lab Ltd Chairperson and CEO exercised stock options and reported related ADS transactions. On March 10, 2026, the reporting person exercised options to acquire 261,092 American Depositary Shares (ADSs) at $1.74 per ADS and received an additional 2,655 ADSs upon vesting of restricted share units (RSUs). To cover taxes on RSU vesting, 116,936 ADSs were automatically sold at $19.41 per ADS. On March 11, 2026, 1,067 ADSs were sold at $19.084 per ADS under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, the reporting person directly held 1,109,905 ADSs, with 461,092 stock options and 7,965 RSUs remaining outstanding. Each ADS represents ten Ordinary Shares of Zai Lab.
Zai Lab Ltd chairperson and CEO Du Ying reported option exercises and share sales under a pre-arranged trading plan. On March 6 and March 9, 2026, Du Ying exercised stock options for a total of 100,000 American Depositary Shares at an exercise price of $1.74 per ADS and then sold 100,000 ADS in open-market transactions at weighted average prices of $19.4187 and $19.0293 per ADS. Following these transactions, Du Ying directly holds 964,161 ADS. The filing notes that each ADS represents ten ordinary shares and that all trades were executed pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025, indicating the sales were pre-scheduled rather than opportunistic.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an open-market sale of 15,569 American Depositary Shares at $19.06 per ADS on March 5, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.
Following this transaction, he holds 3,517 ADS directly. Each ADS represents ten ordinary shares of Zai Lab, and the ADSs and ordinary shares are described as fully fungible.
Zai Lab Ltd chairperson and CEO Du Ying reported exercising stock options and selling shares in early March 2026. On March 4–5, 2026, Du Ying exercised options for a total of 100,000 American Depositary Shares (ADS), described as derivative exercises or conversions at $1.74 per ADS.
Over the same two days, Du Ying sold 100,000 ADS in open-market transactions at weighted average prices of $18.7769, $19.3176, and $19.2211 per ADS. After these trades, Du Ying directly owned 964,161 ADS. Each ADS represents ten ordinary shares, and all trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
Zai Lab Ltd officer Rafael Amado reported an open‑market sale of 10,000 American Depositary Shares (ADS) on 2026-03-03 at a price of $17.38 per ADS. After this transaction, he directly held 42,391 ADS.
Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are fully fungible. The sale was effected under a Rule 10b5‑1 trading plan adopted by the reporting person on November 15, 2025.
Zai Lab Ltd's Chief Legal Officer, identified as an officer of the company, reported an open-market sale of company stock. On 12/16/2025, the reporting person sold 8,651 American Depositary Shares (ADS) of Zai Lab at a price of $17.14 per ADS, as shown in Table I with transaction code "S" for a sale.
After this transaction, the reporting person beneficially owns 19,086 ADS, held directly. Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are fully fungible. The filing notes that this sale was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, indicating the trade was pre-arranged under that plan.
Zai Lab Ltd disclosed insider share movements by its chairperson and CEO, who is also a director. On December 10, 2025, the insider made a bona fide gift of 303,378 American Depositary Shares (ADSs) at a reported price of $0, leaving 586,641 ADSs beneficially owned afterward. On December 11, 2025, the insider received 377,520 ADSs, also at $0, as an annuity payment from the same grantor retained annuity trust, increasing beneficial ownership to 964,161 ADSs. Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are described as fully fungible.
Zai Lab Ltd (ZLAB) reported an insider stock sale by its Chief Legal Officer. On 11/21/2025, the officer sold 14,328 American Depositary Shares (ADS) of Zai Lab in an open-market transaction coded as an "S" sale at a price of $19.78 per ADS. After this transaction, the officer beneficially owned 27,737 ADS, held directly.
Each ADS represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are described as fully fungible. The filing notes that the trade was carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 11/22/2024, indicating it was pre-arranged under that rule’s affirmative defense framework.
Zai Lab (ZLAB) disclosed insider activity by its Chief Financial Officer. On 10/31/2025, 500 American Depositary Shares (ADS) were acquired upon the vesting of restricted share units (RSUs). On 11/03/2025, 240 ADS were sold at $26.831 per ADS to cover taxes associated with the vesting. Following these transactions, the officer directly owned 17,444 ADS.
Each ADS represents ten Ordinary Shares. Each RSU represents a contingent right to receive one ADS, with the grant vesting in equal annual installments over four years beginning on 11/01/2022.